Health AI Central
Peer-Reviewed Publication
Cells2026;15(18)September 18, 2026Journal Article

UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance.

Kodai Abe1,2, Kelly Chong1, Yuta Abe2, Minoru Kitago2, Motonori Edanami2, Yosuke Uematsu2, Yohei Masugi3,4, Akihisa Ueno4,5, Matias A Bustos1,6, Anton J Bilchik7, Yosef Shiloh8, Yuko Kitagawa2, Dave S B Hoon1,9
1Department of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.
2Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
3Department of Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
4Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan.
5Division of Diagnostic Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
6Department of Translational and Precision Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.
7Department of Gastrointestinal and Hepatobiliary Surgery, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.
8David and Inez Myers Laboratory for Cancer Genetics, Department of Human Genetics and Computational Medicine, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
9Advanced Therapeutics and Biomedical Technologies, The Lundquist Institute of Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90504, USA.
PubMed DOI

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is an aggressive biliary tract malignancy with limited treatment options and poor prognosis. Platinum-based drugs are one of the major therapies; however, resistance remains a major therapeutic challenge. Ubiquilin-4 (UBQLN4), a ubiquitin-binding protein implicated in cancer progression and DNA damage responses, is located at chromosome 1q22, a re…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.